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Background: The cluster randomized crossover (CRXO) design is gaining popularity in trial settings where
individual randomization or parallel group cluster randomization is not feasible or practical. In a CRXO trial, not only
are clusters of individuals rather than individuals themselves randomized to trial arms, but also each cluster
participates in each arm of the trial at least once in separate periods of time.
We will review publications of clinical trials undertaken in humans that have used the CRXO design. The aim of this
systematic review is to summarize, as reported: the motivations for using the CRXO design, the values of the CRXO
design parameters, the justification and methodology for the sample size calculations and analyses, and the quality
of reporting the CRXO design aspects.
Methods/Design: We will identify reports of CRXO trials by systematically searching MEDLINE, PubMed, Cochrane
Methodology Register, EMBASE, and CINAHL Plus. In addition, we will search for methodological articles that
describe the CRXO design and conduct citation searches to identify any further CRXO trials. The references of all
eligible trials will also be searched.
We will screen the identified abstracts, and retrieve and assess for inclusion the full text for any potentially relevant
articles. Data will be extracted from the full text independently by two reviewers. Descriptive summary statistics will
be presented for the extracted data.
Discussion: This systematic review will inform both researchers addressing CRXO methodology and trialists
considering implementing the design. The results will allow focused methodological research of the CRXO design,
provide practical examples for researchers of how CRXO trials have been conducted, including any shortcomings,
and highlight areas where reporting and conduct may be improved.
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ReportingBackground
The most commonly used experimental design to assess
the effects of an intervention is the individually random-
ized parallel two-arm trial [1]. However, randomizing indi-
viduals is not always possible, and in many circumstances
groups of people, or ‘clusters’, are instead randomly allo-
cated to the intervention groups. Cluster randomization is
commonly used in the following situations: when contam-
ination may occur if individuals in the same cluster were* Correspondence: sarah.arnup@monash.edu
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unless otherwise stated.randomized to different intervention groups, the interven-
tion is targeted at the cluster level, or for logistical, feasi-
bility, or ethical reasons [2].
Individuals within a cluster tend to have more similar
outcomes than individuals across clusters. For example,
due to case-mix differences of patients presenting to differ-
ent hospitals, patients in the same hospital may have more
similar outcomes than patients across different hospitals.
As a result, a cluster randomized trial usually requires a
larger sample size than an individually randomized trial in
order to achieve the same power to detect the same differ-
ence between groups. Failure to account for the clustering
during analysis can lead to overly precise estimates of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ences about the effectiveness of the intervention [2].
A variation of the parallel group cluster randomized de-
sign is the cluster randomized crossover design (CRXO).
In the CRXO design each cluster receives each interven-
tion at least once in separate periods of time [3,4]. During
each time period the cluster may contain different individ-
uals, the same individuals, or a mixture of both different
and same individuals [5].
Analogous to trials where individuals are randomized
and a crossover is included in the design to improve effi-
ciency, incorporating a crossover into a parallel group
cluster randomized design increases efficiency if the clus-
ter environment remains similar between time periods [5].
The gains in efficiency of a CRXO trial over a parallel
group cluster randomized trial depend upon the number
of clusters, the size of the clusters, the number of time pe-
riods, and the similarity between individuals within the
trial. The similarity in the outcomes of individuals within
a cluster within a time period is typically measured by the
within-cluster within-period intra-cluster correlation coef-
ficient (ICC). The similarity between individuals within
the same cluster, both within the same time period and
across different time periods, is typically measured by the
within-cluster between-period ICC [4,6].
To our knowledge, there have only been limited re-
views of the CRXO trial design. These reviews have
taken place in the introductory sections of methodo-
logical papers with the purpose of illustrating the design
and highlighting the need for appropriate methods of
analysis [3,4,6,7]. Turner et al. [3] reviewed eight trials
[8-15] from 1985 to 2003 and noted that the majority of
these trials did not allow for the within-cluster within-
period and within-cluster between-period correlations in
the analysis of outcomes. In the one trial [8] that did
allow for these correlations in the analysis by using hier-
archical modelling, Turner et al. [3] noted that no justifi-
cation was given for the choice of analysis.
The CRXO design is gaining popularity in settings
where cluster randomization is required, but the parallel
group cluster randomized design is not practical because
it leads to a prohibitively large sample size. However, no
systematic review of the use of the CRXO design has
been performed to date. Such a review will inform both
researchers addressing CRXO methodology and trialists
considering implementing this design.
Objectives
The purpose of this systematic review is to establish
from CRXO publications: the motivations for using the
CRXO design, the values of the CRXO design parame-
ters, the justification and methodology for the sample
size calculations and analyses, and the quality of report-
ing the CRXO design aspects.Methods/Design
Search methods for identification of studies
We will search for reports of CRXO trials that were con-
ducted in humans and reported in English up until April
2014. One author (SA) will search for articles indexed in
MEDLINE, PubMed, Cochrane Methodology Register,
EMBASE and CINAHL Plus. (The search strategies for
Ovid MEDLINE and the additional databases are in
Appendix 1). Ovid was chosen to search MEDLINE be-
cause proximity searches, which cannot be performed
in PubMed, are an essential component of the search
strategy. As PubMed contains some additional publica-
tions not found in MEDLINE, a modified but less sensi-
tive search will be performed using PubMed.
To supplement the above searches, SA will search CRXO
methodology articles for further references to CRXO trials.
A citation search of all identified methodology articles will
be performed in Web of Science. SA and JM will identify
CRXO methodology articles from PubMed using the fol-
lowing search strategy: ((cluster[tiab] AND cross*over[tiab])
OR cluster-crossover[tiab]) AND (method*[tiab] OR design
[tiab] OR calcul*[tiab] OR analy*[tiab]).
Finally the references of all eligible articles will be
screened by SA for further CRXO trials. If the title of
the article or the text of the referring article suggests a
CRXO design was used in the trial then the full text will
be screened for eligibility by two reviewers (SA and AF
or JM). This process will continue until no further eli-
gible articles are identified.
Inclusion criteria
We will include reports of CRXO trials with the following
elements: the trial was undertaken in humans; the alloca-
tion of the intervention was to clusters of individuals rather
than individuals themselves - the allocation does not have
to be at random, since the statistical considerations remain
the same irrespective of the method used to allocate clus-
ters to the sequence of interventions; and each cluster
received each intervention in a sequence over time (conven-
tional crossover design), or at least some clusters crossed
over from one intervention to another (such as two-
treatment-four-sequence designs AA, AB, BA, and BB).
Study selection
Titles and abstracts of all articles identified through the
electronic searches will be imported into EndNote (End-
Note X6, Thomson Reuters, New York, USA) and dupli-
cates removed. Each abstract and title will assessed by one
of five reviewers and a further 50% of abstracts will be
assessed independently by a second reviewer. Full text ar-
ticles will be retrieved when both reviewers answer ‘yes’ or
‘unclear’ to all selection criteria. The full text will not be
retrieved if both reviewers agree that at least one selection
criteria was not met. The full text will be retrieved for the
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‘no’ by one reviewer were assessed as ‘yes’ or ‘unclear’ by
the other reviewer.
Two reviewers will assess the full text articles. Trials will
be included in the review if both reviewers agree that all
selection criteria are met. Trials will be excluded if both
reviewers agree that at least one selection criteria was not
met. For the remaining trials, the decision to include the
trial in the review will be by consensus between the two
reviewers or by referral to a third reviewer.
Data extraction and management
Two reviewers will independently extract data using an
electronic data extraction form developed for this review
(see Additional file 1). The data extraction form has been
piloted by five reviewers in one to three studies each and
adjusted accordingly.
We will extract data for each trial on: identification of the
design in the title or abstract, justification for using the de-
sign, acknowledgement of the underlying assumptions of
the design, demographic details (country, setting, unit of
clustering, type of intervention, and control), characteris-
tics, methods used in the trial (recruitment, randomization,
allocation, and blinding), reporting of baseline characteris-
tics of the trial design, and statistical analysis (methods to
estimate intervention effects and adjustment for covariates).
The extracted design characteristics will include: number
of clusters, number of periods, number of cluster-periods
(clusters × periods), number of individuals in the trial, num-
ber of interventions and the allocation of interventions to
cluster periods, the variability of the number of individuals
between cluster-periods, the reported measure of similarity
between the outcomes of individuals within a cluster within
a given period, and the reported measure of similarity be-
tween outcomes of individuals within a cluster between dif-
ferent periods.
The extracted data will include verbatim free text and
categorization of the text into pre-specified options where
possible. Any free text that does not fall into the pre-
specified options will be categorized through discussion
between reviewers. If data are not reported in the article or
are incomplete, ‘not stated’ will be recorded on the data ex-
traction form. Trialists will not be contacted, since we in-
tend to examine trialists’ reported motivations. Differences
in data extraction will be resolved through discussion until
consensus is reached, or by referral to a third reviewer.
Analysis
The flow of information through the systematic review will
be reported in accordance with the PRISMA statement [16].
We will calculate descriptive summary statistics using
frequencies and percentages of responses to categorical
data. Free text will be classified and frequencies and
percentages of the categories will be presented in theanalysis. For continuous data the range and mean with
SD or median with IQR will be presented as appropriate.
Discussion
Our systematic review is designed to establish the moti-
vations for using the CRXO design, the values of the
CRXO design parameters, how both the sample size cal-
culations and analyses account for the correlation struc-
ture and the incorporation of any covariates, and the
quality of reporting the CRXO design, including the
reporting of the correlation structure.
Strengths and limitations of our protocol
To our knowledge, this will be the first systematic review of
CRXO trials with a rigorous and pre-specified method-
ology. We have pre-defined our screening and data ex-
traction forms. Where possible, reviewers will classify
article text according to pre-defined categories rather than
categorize the free text after all the data has been captured.
Pre-specifying the methodology and data collection reduces
the risk of introducing bias into the review. The full text
screening and data extraction will be performed by two re-
viewers. A subset of the abstract screening will be per-
formed by two reviewers. The data abstraction form has
been piloted on several articles by more than one reviewer.
A limitation of this review is the difficulty in identify-
ing CRXO trials. Trials that use cluster randomization
frequently do not use the word ‘cluster’ in the title or ab-
stract, and it is often not apparent that the allocation of
the intervention was at the cluster level unless the
methods are read in the full text article [17]. In an at-
tempt to limit missed studies, the search strategy en-
compasses units that are typically cluster randomized
(such as schools or hospitals) and the references of all
eligible articles will be searched. In addition, a search for
CRXO methodology articles, and articles which cite
them, will be undertaken to identify further trials.
CRXO designs may be employed in areas outside of clin-
ical trials undertaken in humans, for example, variants of
split-plot designs in agricultural sciences. There may be
studies in behavioral, social, or educational sciences which
will be missed by the search methodology employed in this
review as our search is restricted to a limited number of
databases. However, while the application of the CRXO
design in these fields may be interesting from a methodo-
logical perspective, the focus of this systematic review is
cluster randomization and crossover of interventions in
human clinical trials in health.
We are interested in the design, methods, and motiva-
tions for using the CRXO design. Our ability to assess
some of these elements may be limited because of missing
and incomplete reporting in the trial publications. While
contact with trial authors may help establish some of
missing elements, we do not plan to contact authors since
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makers are generally reliant on only the information
within publications, and therefore examining the quality
and completeness of reporting is important. Knowledge of
the adequacy of reporting is an essential step in developing
reporting guidelines for such trials, if a need is found [18].
Both the stepped wedge design and the split-cluster de-
sign have similarities with the CRXO design. However,
these designs were not considered in this review. A system-
atic review of the stepped wedge design was performed by
Mdege et al. [19]. The split-cluster design does not have
distinct time periods, so any similarity between the sub-
clusters at a single point in time is likely to be different in
nature to the similarity in clusters between time periods.Implications of this research
Results from our systematic review will allow for focused
methodological research of the CRXO design. The re-
sults will also provide practical examples for researchers
of how CRXO trials have been conducted, including any
shortcomings, and highlight areas where reporting and
conduct may be improved.Appendix 1: Search strategies
Ovid MEDLINE search
CROSS OVER TERMS
1. (cross-over or cross?over or "cross* over").tw.
2. (switch-over or switch?over or "switch* over" or switch-
back or switch?back or "switch* back" or switched).tw.
3. ((change-over or change?over or "change* over") not
((change-over or change?over or "change* over") adj1
time)).tw.
4. (ab*ba* adj3 design*).tw.
5. exp Cross-Over Studies/
6. 1 or 2 or 3 or 4 or 5
CLUSTER ALLOCATION TERMS
7. ((unit$1 or school$1 or hospital$1 or cluster* or region
$1 or ward* or practice* or communit* or population* or
facility or facilities or practitioner*) adj15 random*).tw.
8. ((unit$1 or school$1 or hospital$1 or cluster* or region
$1 or ward* or practice* or communit* or population* or
facility or facilities or practitioner*) adj15 interven*).tw.
9. ((group* adj random*) or (group* adj interven*)).tw.




13. 12 not 11COMBINE CONCEPTS
14. 6 and 10
15. 14 not 13
PubMed search
CROSS OVER TERMS
1. "cross-over"[tiab] OR crossover[tiab] OR "cross
over" [tiab] OR "crossed over"[tiab]
2. "switch-over"[tiab] OR switchover[tiab] OR
"switch over"[tiab] OR "switch-back"[tiab] OR
switchback[tiab] OR "switch back"[tiab] OR
switched[tiab]
3. (change-over[tiab] OR changeover[tiab] OR "change
over"[tiab] OR "changed over"[tiab] OR "changes
over"[tiab]) not ("change-over time"[tiab] OR
"changeover time"[tiab] OR "change over time"[tiab]




6. #1 OR #2 OR #3 OR #4 OR #5
CLUSTER ALLOCATION TERMS
7. (cluster-randomi*[tiab] OR "cluster randomized"
[tiab] OR "cluster randomised"[tiab] OR "cluster
randomization"[tiab] OR "cluster randomization"
[tiab])
HUMANS ONLY
8. (Animals[mh] NOT Humans[mh])
COMBINE CONCEPTS
9. #6 AND #7
10. #9 NOT 8
11. #10 NOT MEDLINE[sb]
EMBASE search via embase.com
CROSS OVER TERMS
1. (cross-over or crossover or "cross over" or "crosses
over" or "crossed over" or "crossing over"):ti:ab
2. (switch-over or switchover or "switch over" or
"switches over" or "switched over" or switch-back or
"switchback" or "switch back" or "switches back" or
"switched back" or switched):ti:ab
3. ((change-over or changeover or "change over" or
"changes over" or "changed over") not ((change-over
or changeover or "change over" or "changes over" or
"changed over") near/1 time)):ti:ab
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5. “crossover procedure”/exp
6. #1 or #2 or #3 or #4 or #5
CLUSTER ALLOCATION TERMS
7. ((unit or units or school or schools or hospital or
hospitals or cluster or clusters or region or regions or
ward or wards or practice or practices or community
or communities or population or populations or facility
or facilities or practitioner or practitioners) near/15
(random or randomly or randomise or randomize
or randomised or randomized or randomises or
randomizes or randomisation or randomization)):ti:ab
8. ((unit or units or school or schools or hospital or
hospitals or cluster or clusters or region or regions or
ward or wards or practice or practices or community
or communities or population or populations or facility
or facilities or practitioner or practitioners) near/15
(intervene or intervention or interventions)):ti:ab
9. ((group or groups or grouped) near/1 (random or
randomly or randomise or randomize or randomised
or randomized or randomises or randomizes or
randomisation or randomization)):ti:ab or ((group or
groups or grouped) near/1 (intervene or intervention
or interventions)):ti:ab
10. #7 or #8 or #9
HUMANS ONLY
11. ‘animal’ not ‘human’
COMBINE CONCEPTS
12. #6 and #10
13. #12 not #11
14. #13 not ‘medline’
CINAHL Plus search
CROSS OVER TERMS
1. TI (("cross-over" or "cross?over" or "cross* over")) OR
AB (("cross-over" or "cross?over" or "cross* over"))
2. TI (("switch-over" or "switch?over" or "switch* over"
or "switch-back" or "switch?back" or "switch* back"
or switched)) OR AB (("switch-over" or "switch?
over" or "switch* over" or "switch-back" or "switch?
back" or "switch* back" or switched))
3. TI ((("change-over" or "change?over" or "change*
over") not (("change-over" or "change?over" or
"change* over") n1 time))) OR AB ((("change-over" or
"change?over" or "change* over") not (("change-over"
or "change?over" or "change* over") n1 time)))
4. TI (ab*ba* n3 design*) OR AB (ab*ba* n3 design*)5. (MH "Crossover Design")
6. S1 or S2 or S3 or S4 or S5
CLUSTER ALLOCATION TERMS
7. TI (((unit or units or school or schools or hospital or
hospitals or cluster or clusters or region or regions or
ward or wards or practice or practices or community
or communities or population or populations or
facility or facilities or practitioner or practitioners) n15
random*)) OR AB (((unit or units or school or schools
or hospital or hospitals or cluster or clusters or region
or regions or ward or wards or practice or practices
or community or communities or population or
populations or facility or facilities or practitioner
or practitioners) n15 random*))
8. TI (((unit or units or school or schools or hospital or
hospitals or cluster or clusters or region or regions or
ward or wards or practice or practices or community
or communities or population or populations or
facility or facilities or practitioner or practitioners) n15
interven*)) OR AB (((unit or units or school or
schools or hospital or hospitals or cluster or clusters
or region or regions or ward or wards or practice or
practices or community or communities or population
or populations or facility or facilities or practitioner or
practitioners) n15 interven*))
9. TI (((group* n1 random*) or (group* n1 interven*)))
OR AB (((group* n1 random*) or (group* n1
interven*)))




13. S12 not S11
COMBINE CONCEPTS
14. S6 and S10
15. S14 not S13
16. Exclude MEDLINE
Additional file
Additional file 1: This additional file contains the data that will be
extracted from included studies.
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